Our highly predictive and non-invasive prognostic/diagnostic applications have the potential to fundamentally improve the treatment of disease


3-Dimensional Telomere Technology

Telomeres are sections of DNA at the ends of chromosomes that act as protective caps. Healthy telomeres safeguard the entire genome, regulating cell division and maintaining its integrity and stability.

Dysfunction or loss of telomeres leads to genome alterations such as chromosomal fusions, uncontrolled cell growth and genomic instability; which is a causal factor in the development of genetic diseases including cancer and neurodegenerative diseases (CNS).

Our proprietary technology TeloView®, quantifies genomic instability by measuring the 3D structure and the spatial organization of telomeres. It is designed to provide important actionable information regarding the aggressiveness of disease and potential response to treatment.

TeloView SMM: Description & Clinical Validation

Telo’s lead product is TeloView SMM, a high-complexity molecular assay available for clinical use to provide information to physicians treating patients with Smouldering Multiple Myeloma. Through proprietary telomere-based analysis, TeloView SMM selects high-risk SMM patients who are likely to benefit from earlier treatment intervention while identifying the larger subset of low-risk SMM patients who have a more stable form of the disease and do not require immediate treatment.

These claims were validated by a study conducted in collaboration with the Mayo Clinic and Dr. Shaji Kumar in 2022-2023. In the study, a blinded cohort of 178 SMM patients were stratified to their respective risk groups by TeloView with greater than 80% accuracy. The achieved characteristics of the TeloView SMM assay outperform competitive tests that are currently available in the clinic.